Interim report for the fourth quarter and full year 2013

March 3, 2014


  • Continued progress on the start-up of NormoCort™ Phase 3 development – the first patient expected to be enrolled within the next few months

  • Acquired remaining shares in BioPancreate Inc. – holding the rights to a potential break-through treatment concept for Diabetes type 1 and 2

  • Net loss for the Group was SEK 10.3 million for the fourth quarter and SEK 32.9 million for the full year, compared with a net loss of SEK 8.1 million in the fourth quarter 2012 and SEK 23.7 million for the full year 2012

  • The cost level in the fourth quarter reflects higher G&A and other operating costs related to the preparations for a public exchange listing, as well as unrealized currency losses due to a generally weaker NOK

  • Liquid assets amounted to SEK 97.1 million at the end of 2013, up from SEK 24.3 million at the end of 2012

For the full report see attached pdf-file.

E-mail: [email protected]



© 2021 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Dublin Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V16 03/2020

  • Ireland Address:
    Suite 206, Fitzwilliam Hall
    Fitzwilliam Place, Dublin 2, D02 T292
  • U.S. Address:
    900 Northbrook Drive, Suite 200
    Trevose, PA 19053
    United States

Phone: +1 610-254-9200
[email protected]

Privacy Statement
Compliance Program